[{"id":"0585dfcf-9f5e-4af9-b8c7-2ca599943391","acronym":"MATINS","url":"https://clinicaltrials.gov/study/NCT03733990","created_at":"2021-01-18T18:17:18.236Z","updated_at":"2024-07-02T16:35:28.087Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)","source_id_and_acronym":"NCT03733990 - MATINS","lead_sponsor":"Faron Pharmaceuticals Ltd","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Clevegen (bexmarilimab)"],"overall_status":"Completed","enrollment":" Enrollment 216","initiation":"Initiation: 12/03/2018","start_date":" 12/03/2018","primary_txt":" Primary completion: 09/06/2023","primary_completion_date":" 09/06/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2023-11-27"},{"id":"f5873dc7-875e-4150-95cc-27b4d9c11802","acronym":"","url":"https://clinicaltrials.gov/study/NCT05171062","created_at":"2021-12-28T19:16:15.615Z","updated_at":"2024-07-02T16:35:42.490Z","phase":"Phase 1","brief_title":"Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05171062","lead_sponsor":"The University of Texas Health Science Center at San Antonio","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Clevegen (bexmarilimab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-07-20"}]